Opko Health Inc. (OQ:OPK)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 4400 Biscayne Blvd
MIAMI FL 33137-3212
Tel: 1-212-8383777
Website: www.opko.com
IR: See website
<
Key People
Phillip Frost
Chairman of the Board, Chief Executive Officer
Jane H. Hsiao
Vice Chairman of the Board, Chief Technical Officer
Adam E. Logal
Chief Financial Officer, Senior Vice President
Jon Roger Cohen
Executive Chairman of BioReference Laboratories
Geoff Monk
President of BioReference
Steven D. Rubin
Executive Vice President - Administration, Director
Business Overview
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Financial Overview
For the three months ended 31 March 2019, Opko Health Inc. revenues decreased 13% to $222.5M. Net loss increased 87% to $80.8M. Revenues reflect Diagnostics segment decrease of 15% to $178.9M, United States segment decrease of 14% to $184.9M, Chile segment decrease of 33% to $7.9M, Spain segment decrease of 20% to $4.4M. Higher net loss reflects Diagnostics segment loss increase from $8M to $33.6M.
Employees: 5,690 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $1,359M as of Mar 31, 2019
Annual revenue (TTM): $957.81M as of Mar 31, 2019
EBITDA (TTM): -$85.07M as of Mar 31, 2019
Net annual income (TTM): -$190.69M as of Mar 31, 2019
Free cash flow (TTM): -$147.43M as of Mar 31, 2019
Net Debt Last Fiscal Year: $121.16M as of Mar 31, 2019
Shares outstanding: 615,601,045 as of Apr 24, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization